JP2000517167A5 - - Google Patents

Download PDF

Info

Publication number: JP2000517167A5
Authority: JP; Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP1998507410A

Other languages

English (en)

Japanese (ja)

Other versions

JP2000517167A (ja

JP4301576B2 (ja

Filing date

1997-08-01

Publication date

2005-04-07

1997-08-01 Application filed filed Critical

1997-08-01 Priority claimed from PCT/CA1997/000540 external-priority patent/WO1998005769A2/en

2000-12-26 Publication of JP2000517167A publication Critical patent/JP2000517167A/ja

2005-04-07 Publication of JP2000517167A5 publication Critical patent/JP2000517167A5/ja

2009-07-22 Application granted granted Critical

2009-07-22 Publication of JP4301576B2 publication Critical patent/JP4301576B2/ja

2017-08-01 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

JP50741098A 1996-08-02 1997-08-01 リボヌクレオチドレダクターゼのｒ１およびｒ２成分に対して指向される抗腫瘍アンチセンス配列 Expired - Fee Related JP4301576B2 (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US2304096P	1996-08-02	1996-08-02
US60/023,040		1996-08-02
US3995997P	1997-03-07	1997-03-07
US60/039,959		1997-03-07
PCT/CA1997/000540 WO1998005769A2 (en)	1996-08-02	1997-08-01	Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase

Publications (3)

Publication Number	Publication Date
JP2000517167A JP2000517167A (ja)	2000-12-26
JP2000517167A5 true JP2000517167A5 (2)	2005-04-07
JP4301576B2 JP4301576B2 (ja)	2009-07-22

Family

ID=26696655

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP50741098A Expired - Fee Related JP4301576B2 (ja)	1996-08-02	1997-08-01	リボヌクレオチドレダクターゼのｒ１およびｒ２成分に対して指向される抗腫瘍アンチセンス配列

Country Status (12)

Country	Link
US (1)	US5998383A (2)
EP (1)	EP0917569B1 (2)
JP (1)	JP4301576B2 (2)
CN (1)	CN1189562C (2)
AT (1)	ATE309345T1 (2)
AU (1)	AU738592C (2)
CA (1)	CA2262776C (2)
DE (1)	DE69734589T2 (2)
ES (1)	ES2256893T3 (2)
IL (2)	IL128124A0 (2)
NZ (1)	NZ333802A (2)
WO (1)	WO1998005769A2 (2)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1223831A (en)	1982-06-23	1987-07-07	Dean Engelhardt	Modified nucleotides, methods of preparing and utilizing and compositions containing the same
US7223849B1 (en) *	1996-07-01	2007-05-29	Genesense Technologies Inc.	Oligonucleotides from the untranslated regions of housekeeping genes and methods of using same to modulate cell growth
US6593305B1 (en)	1996-08-02	2003-07-15	Genesense Technologies Inc.	Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
EP0971731B1 (en)	1997-03-19	2004-05-12	GeneSense Technologies Inc.	Suppression of malignancy utilizing ribonucleotide reductase r1
US6835395B1 (en)	1997-05-14	2004-12-28	The University Of British Columbia	Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
US6610539B1 (en) *	1997-07-10	2003-08-26	Genesense Technologies, Inc.	Antisense oligonucleotide sequences as inhibitors of microorganisms
EP1584681A3 (en) *	1997-07-10	2005-11-09	GeneSense Technologies Inc.	Antisense oligonucleotide sequences as inhibitors of microorganisms
US6506559B1 (en)	1997-12-23	2003-01-14	Carnegie Institute Of Washington	Genetic inhibition by double-stranded RNA
WO1999049029A1 (en) *	1998-03-20	1999-09-30	Benitec Australia Ltd	Control of gene expression
AUPP249298A0 (en)	1998-03-20	1998-04-23	Ag-Gene Australia Limited	Synthetic genes and genetic constructs comprising same I
EP2314700A1 (en) *	1999-01-28	2011-04-27	Medical College of Georgia Research Institute, Inc	Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
US6121000A (en) *	1999-02-11	2000-09-19	Genesense Technologies, Inc.	Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
US20040138168A1 (en) *	1999-04-21	2004-07-15	Wyeth	Methods and compositions for inhibiting the function of polynucleotide sequences
US6642033B1 (en)	1999-07-20	2003-11-04	V.I. Technologies, Inc.	Nucleic acids for detecting parvovirus and methods of using same
US6423885B1 (en)	1999-08-13	2002-07-23	Commonwealth Scientific And Industrial Research Organization (Csiro)	Methods for obtaining modified phenotypes in plant cells
CN1301816A (zh) *	1999-12-27	2001-07-04	上海博德基因开发有限公司	一种新的多肽——核苷酸还原酶10和编码这种多肽的多核苷酸
MXPA02009069A (es) *	2000-03-17	2004-04-05	Benitec Australia Ltd	Silenciamiento genetico.
EP1229134A3 (en) *	2001-01-31	2004-01-28	Nucleonics, Inc	Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
DE10131148A1 (de) *	2001-06-28	2003-01-16	I P L Internat Pharmaceutics L	Xenogene Oligo- oder/und Polyribonukleotide als Mittel zur Behandlung von malignen Tumoren
WO2004070033A1 (en) *	2003-02-10	2004-08-19	Genesense Technologies Inc.	Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer
CA2524255C (en) *	2003-03-21	2014-02-11	Academisch Ziekenhuis Leiden	Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
CA2526393A1 (en) *	2003-05-21	2004-12-02	Genesense Technologies Inc.	Antisense oligonucleotides directed to ribonucleotide reductase r1 and uses thereof in the treatment of cancer
WO2004106518A1 (en) *	2003-05-31	2004-12-09	Genesense Technologies Inc.	Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer
JP2007529199A (ja)	2003-10-23	2007-10-25	イルミジェンバイオサイエンシーズ，インコーポレイテッド	ウイルス感染に対する抵抗性に関連する遺伝子である、ｏａｓ１における変異の検出
AU2005203822A1 (en) *	2004-01-12	2005-07-21	Lorus Therapeutics Inc.	Antisense oligonucleotides directed to ribonucleotide reductase R2 and uses thereof in combination therapies for the treatment of cancer
US8029815B2 (en) *	2004-04-28	2011-10-04	Elford Howard L	Methods for treating or preventing restenosis and other vascular proliferative disorders
CA2566519C (en) *	2004-05-14	2020-04-21	Rosetta Genomics Ltd.	Micrornas and uses thereof
US7968762B2 (en) *	2004-07-13	2011-06-28	Van Andel Research Institute	Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
CA2577036A1 (en) *	2004-08-18	2006-02-23	Genesense Technologies Inc.	Small interfering rna molecules against ribonucleotide reductase and uses thereof
US20060185027A1 (en) *	2004-12-23	2006-08-17	David Bartel	Systems and methods for identifying miRNA targets and for altering miRNA and target expression
EP1866414B9 (en) *	2005-03-31	2012-10-03	Calando Pharmaceuticals, Inc.	Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
JO2660B1 (en)	2006-01-20	2012-06-17	نوفارتيس ايه جي	Pi-3 inhibitors and methods of use
TW200808739A (en)	2006-04-06	2008-02-16	Novartis Vaccines & Diagnostic	Quinazolines for PDK1 inhibition
EP2030615A3 (en) *	2007-08-13	2009-12-02	ELFORD, Howard L.	Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
US20100204305A1 (en) *	2007-12-11	2010-08-12	Lorus Therapeutics Inc.	Small interfering rna molecules against ribonucleotide reductase and uses thereof
EP2240475B1 (en)	2007-12-20	2013-09-25	Novartis AG	Thiazole derivatives used as pi 3 kinase inhibitors
WO2010027279A2 (en) *	2008-09-04	2010-03-11	Genesis Research And Development Corporation Limited	Compositions and methods for the treatment and prevention of neoplastic disorders
EP2350264A4 (en)	2008-11-06	2012-08-29	Univ Johns Hopkins	TREATMENT OF CHRONIC INFLAMMATION OF THE RESPIRATORY TRACT
US8293753B2 (en)	2009-07-02	2012-10-23	Novartis Ag	Substituted 2-carboxamide cycloamino ureas
AR082418A1 (es)	2010-08-02	2012-12-05	Novartis Ag	Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
EP2630240A1 (en) *	2010-10-18	2013-08-28	Arrowhead Research Corporation	Compositions and methods for inhibiting expression of rrm2 genes
JP5963777B2 (ja)	2011-01-31	2016-08-03	ノバルティスアーゲー	新規ヘテロ環誘導体
CN104039790B (zh)	2011-10-28	2016-04-13	诺华股份有限公司	嘌呤衍生物及它们在治疗疾病中的应用
KR20150009540A (ko)	2012-05-16	2015-01-26	노파르티스 아게	Pi-3 키나제 억제제에 대한 투여 요법
SI3076969T1 (sl)	2013-12-06	2021-12-31	Novartis Ag	Režim omderjanja izooblike alfa selektivnega zaviralca fosfatidilino- zitol 3-kinaze
US20180280370A1 (en)	2015-11-02	2018-10-04	Novartis Ag	Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
WO2018060833A1 (en)	2016-09-27	2018-04-05	Novartis Ag	Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5681747A (en) *	1992-03-16	1997-10-28	Isis Pharmaceuticals, Inc.	Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
EP0690869A1 (en) *	1993-03-23	1996-01-10	The Board Of Trustees Of The Leland Stanford Junior University	Cellular regulation with riboregulators

1997
- 1997-08-01 CA CA002262776A patent/CA2262776C/en not_active Expired - Fee Related
- 1997-08-01 AU AU36175/97A patent/AU738592C/en not_active Ceased
- 1997-08-01 ES ES97932690T patent/ES2256893T3/es not_active Expired - Lifetime
- 1997-08-01 DE DE69734589T patent/DE69734589T2/de not_active Expired - Lifetime
- 1997-08-01 CN CNB971981639A patent/CN1189562C/zh not_active Expired - Fee Related
- 1997-08-01 IL IL12812497A patent/IL128124A0/xx active IP Right Grant
- 1997-08-01 JP JP50741098A patent/JP4301576B2/ja not_active Expired - Fee Related
- 1997-08-01 WO PCT/CA1997/000540 patent/WO1998005769A2/en not_active Ceased
- 1997-08-01 EP EP97932690A patent/EP0917569B1/en not_active Expired - Lifetime
- 1997-08-01 AT AT97932690T patent/ATE309345T1/de not_active IP Right Cessation
- 1997-08-01 NZ NZ333802A patent/NZ333802A/en not_active IP Right Cessation
- 1997-08-01 US US08/904,901 patent/US5998383A/en not_active Expired - Lifetime
1999
- 1999-01-19 IL IL128124A patent/IL128124A/en not_active IP Right Cessation

Publication	Publication Date	Title
JP2000504714A5 (2)	2004-11-11
JP2001503254A5 (2)	2005-06-16
JP2000507471A5 (2)	2004-12-02
JP2000516515A5 (2)	2005-04-07
JP2000512005A5 (2)	2005-01-13
JP2001517381A5 (2)	2004-10-14
JP2001502151A5 (2)	2005-06-16
JP2000513648A5 (2)	2005-03-10
JP2000510108A5 (2)	2004-12-09
JP2000505719A5 (2)	2004-11-18
JP2001506735A5 (2)	2005-07-14
JP2001504036A5 (2)	2008-03-06
JP2000509829A5 (2)	2005-05-12
JP2001505463A5 (2)	2005-08-11
JP2001503917A5 (2)	2005-07-14
JP2001507106A5 (2)	2005-08-11
JP2001503601A5 (2)	2004-12-02
JP2000508005A5 (2)	2004-12-02
JP2000517167A5 (2)	2005-04-07
JP2000517213A5 (2)	2005-04-07
JP2001505287A5 (2)	2005-07-14
JP2000509067A5 (2)	2004-12-09
JP2000500912A5 (2)	2005-02-10
JP2000506032A5 (2)	2004-11-11
JP2000508665A5 (2)	2005-01-13